{
  "docId": "019de071-38a0-778d-8d39-45a206af86ac",
  "docSlug": "8e68c7763c84d1b485e12f828c3b0d7e",
  "documentTitle": "argenx SE | Investor Day Presentation Deck | 69 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 69,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "key_messages",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The slide illustrates the diversity of autoantibodies in myositis patients, supporting the thesis that a broad-acting therapy like Efgartigimod is effective.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-38a0-778d-8d39-45a206af86ac/29",
  "deckHref": "/decks/019de071-38a0-778d-8d39-45a206af86ac",
  "deckJsonHref": "/decks/019de071-38a0-778d-8d39-45a206af86ac.json",
  "deckAnchorHref": "/decks/019de071-38a0-778d-8d39-45a206af86ac#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.77
      },
      "kind": "callout",
      "text": "Defining new myositis biology",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9341c6b9-7efe-4691-897b-20ed0726d062",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.35,
        "y": 0.25
      },
      "kind": "chart",
      "text": "ASyS (100% MSA+)",
      "attrs": null,
      "subkind": "pie",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03a1abe8-7a05-4987-8392-bf3d5e8d4b5b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "chart",
      "text": "IMNM (70% MSA+)",
      "attrs": null,
      "subkind": "pie",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "88843148-dd77-489c-a4eb-c4549cc0ca7e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.65,
        "y": 0.25
      },
      "kind": "chart",
      "text": "DM (75% MSA+)",
      "attrs": null,
      "subkind": "pie",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8f2e2c4c-5b3e-4e4a-aa12-b0f390f3a467",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.1,
        "y": 0.88
      },
      "kind": "paragraph",
      "text": "Myositis patients can have myositis-specific autoantibodies (MSA+), myositis-associated autoantibodies (MAA+) or autoantibodies against yet unknown targets",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "27acc71e-071a-499c-87f9-be2d37eeb566",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Efgartigimod Designed to Clear IgG Autoantibodies Regardless of Target Antigen",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "73cfa687-c7e1-4d6d-998d-df9227672841",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 43,
      "from": 29,
      "beatId": "002ee641-6d99-4db6-a151-22313bbe3e4f",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "Data supporting Efgartigimod's effectiveness",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 43,
      "from": 29,
      "name": "Aha Moment",
      "slug": "03-aha-moment",
      "bestFor": "Data-heavy sections, research findings, analytical arguments",
      "matchId": "2d58beec-e58f-42d6-98ee-47f2b7cb1adf",
      "evidence": "Data presentation and analysis",
      "position": 1,
      "objective": "Reveal the potential of Efgartigimod",
      "structure": "The Problem/Question -> What the Data Shows -> The Insight",
      "confidence": 0.8,
      "description": "Establish a tension, present data, then deliver the insight that changes everything"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}